MetaCap

Aktis Oncology Inc. (AKTS)

NASDAQ: AKTSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

16.15-0.25 (-1.52%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AKTS stock chart

Technical analysis

Key statistics

All statistics
Market cap
$901.14M
EPS (TTM)
-$1.80
52-week range
13.96 – 34.19
Day range
16.00 – 16.74
Volume / Avg
374.79K / 408.46K
Beta
—

52-week range

$13.96$34.19

AKTS stock today

Shares of Aktis Oncology (AKTS) finished lower on Nov 20 at $16.15, a drop of 1.52% or $0.25 per share, versus the S&P 500's 3.70% decline. Shares are 52.8% below their 52-week high of $34.19, set on Jun 30, 2026 and 15.7% above the 52-week low of $13.96, near the bottom of the past year's range. Aktis Oncology has posted a net loss over the last twelve months (EPS of -$1.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Aktis Oncology

Company profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Matthew Roden Ph.D.
Headquarters
Boston, MA
Employees
79
IPO year
2026

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$35.88+122.17%

  • Strong buy 1
  • Buy 9
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $33.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.54 vs $-0.47
Surprise
-14.89%

AKTS news

All AKTS news

Aktis Oncology peers

Health Care sector
AKTS peer companies
CompanyPrice% ChgMarket capCompare
SVRASavara Inc.4.26-18.23%$939.86Mvs AKTS
MLTXMoonLake Immunotherapeutics Class A11.07+0.36%$942.13Mvs AKTS
CYRXCryoPort Inc.19.05-2.56%$964.87Mvs AKTS
SPTXSeaport Therapeutics Inc.18.05-1.47%$966.23Mvs AKTS
LTGOLatigo Biotherapeutics Inc.13.00-1.81%$861.89Mvs AKTS
MTRIMentari Therapeutics Inc.14.70-3.57%$856.94Mvs AKTS
OMEROmeros Corporation13.21-5.71%$983.66Mvs AKTS
PHARPharming Group N.V. ADS11.54-5.10%$816.78Mvs AKTS

Indexes, lists and sector

Aktis Oncology stock FAQ

What is Aktis Oncology's stock price today?

AKTS last traded at $16.15 as of Nov 20, 4:00 PM EST, down 1.52% on the day. Prices are delayed at least 15 minutes.

Who is Aktis Oncology's CEO?

Dr. Matthew Roden Ph.D. is the chief executive officer of Aktis Oncology Inc., which has about 79 employees.

What is the AKTS 52-week high?

The 52-week high for AKTS is $34.19 and the 52-week low is $13.96. The stock is currently 52.8% below its high.

Compare AKTS